{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:13:31Z","timestamp":1793654011955,"version":"4.5.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T00:00:00Z","timestamp":1318464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T00:00:00Z","timestamp":1318464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Fatigue is prevalent in primary Sj\u00f6gren's syndrome (pSS), and contributes to the considerably reduced health related quality of life in this disease. The symptom is included in proposed disease activity and outcome measures for pSS. Several studies indicate that there is an inflammatory component of fatigue in pSS and other chronic inflammatory rheumatic diseases. The purpose of this study was to investigate fatigue change in pSS in a longitudinal study, and explore whether any clinical or laboratory variables at baseline, including serum cytokines, were associated with a change in fatigue scores over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A clinical and laboratory investigation of 141 patients fulfilling the American-European consensus criteria of pSS was undertaken in the period May 2004 to April 2005. Median time since diagnosis was 5.5 years. Examinations included the fatigue questionnaires: fatigue severity scale (FSS), fatigue visual analogue scale (VAS), functional assessment of chronic illness therapy - fatigue (FACIT-F) and medical outcome study short form-36 (SF-36) vitality, which were repeated in a follow-up investigation in January and February 2010.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 122 patients (87%) responded at both time-points. Thirty-five percent of patients experienced a clinically significant FSS increase. On the group level, fatigue measures did not change except that there was a slight deterioration in SF-36 vitality score. High serum anti-Sj\u00f6gren's syndrome A antigen (anti-SSA) showed weak associations with high baseline fatigue, and patients with increasing fatigue had lower baseline unstimulated whole salivary volume. Weak associations between increasing fatigue and serum immunoglobulin G (IgG), and the pro-inflammatory cytokine interleukin-17 (IL-17), were observed. Baseline sicca symptoms correlated with higher fatigue both at baseline and with increasing fatigue over time. Linear regression analysis did not identify any predictive ability of clinical or laboratory measures on fatigue change over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fatigue remained mainly unchanged over time. Using multivariate models did not reveal any clinical or laboratory predictors of fatigue change over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar3487","type":"journal-article","created":{"date-parts":[[2011,11,25]],"date-time":"2011-11-25T14:16:20Z","timestamp":1322230580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A five-year prospective study of fatigue in primary Sj\u00f6gren's syndrome"],"prefix":"10.1186","volume":"13","author":[{"given":"Karstein","family":"Haldorsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvar","family":"Bjelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Isine","family":"Bolstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Gorgas","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"3243_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1196\/annals.1422.046","volume":"1108","author":"R Jonsson","year":"2007","unstructured":"Jonsson R, Bolstad AI, Brokstad KA, Brun JG: Sj\u00f6gren's syndrome--a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci. 2007, 1108: 433-447. 10.1196\/annals.1422.046.","journal-title":"Ann N Y Acad Sci"},{"key":"3243_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00019052-199612000-00011","volume":"9","author":"LB Krupp","year":"1996","unstructured":"Krupp LB, Pollina DA: Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996, 9: 456-460. 10.1097\/00019052-199612000-00011.","journal-title":"Curr Opin Neurol"},{"key":"3243_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/ard.2003.011825","volume":"63","author":"A Hartkamp","year":"2004","unstructured":"Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GL, Derksen RH: Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sj\u00f6gren's syndrome. Ann Rheum Dis. 2004, 63: 1335-1337. 10.1136\/ard.2003.011825.","journal-title":"Ann Rheum Dis"},{"key":"3243_CR4","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/art.24311","volume":"59","author":"B Segal","year":"2008","unstructured":"Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, Patel K, Novitzke J, Rohrer M, Gopalakrishnan R, Myers S, Nazmul-Hossain A, Emamian E, Huang A, Rhodus N, Moser K: Prevalence, severity, and predictors of fatigue in subjects with primary Sj\u00f6gren's syndrome. Arthritis Rheum. 2008, 59: 1780-1787. 10.1002\/art.24311.","journal-title":"Arthritis Rheum"},{"key":"3243_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14034940410028406","volume":"33","author":"A Lerdal","year":"2005","unstructured":"Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T: Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health. 2005, 33: 123-130. 10.1080\/14034940410028406.","journal-title":"Scand J Public Health"},{"key":"3243_CR6","first-page":"143","volume":"32","author":"SR Pillemer","year":"2005","unstructured":"Pillemer SR, Smith J, Fox PC, Bowman SJ: Outcome measures for Sj\u00f6gren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol. 2005, 32: 143-149.","journal-title":"J Rheumatol"},{"key":"3243_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1365-2362.2010.02303.x","volume":"40","author":"A Campar","year":"2010","unstructured":"Campar A, Isenberg DA: Primary Sj\u00f6gren's syndrome activity and damage indices comparison. Eur J Clin Invest. 2010, 40: 636-644. 10.1111\/j.1365-2362.2010.02303.x.","journal-title":"Eur J Clin Invest"},{"key":"3243_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000135622","volume":"15","author":"AG Tzioufas","year":"2008","unstructured":"Tzioufas AG, Tsonis J, Moutsopoulos HM: Neuroendocrine dysfunction in Sj\u00f6gren's syndrome. Neuroimmunomodulation. 2008, 15: 37-45.","journal-title":"Neuroimmunomodulation"},{"key":"3243_CR9","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/rheumatology\/keq023","volume":"49","author":"L Theander","year":"2010","unstructured":"Theander L, Strombeck B, Mandl T, Theander E: Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sj\u00f6gren's syndrome?. Rheumatology (Oxford). 2010, 49: 1177-1183. 10.1093\/rheumatology\/keq023.","journal-title":"Rheumatology (Oxford)"},{"key":"3243_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P: Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008, 67: 1541-1544.","journal-title":"Ann Rheum Dis"},{"key":"3243_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H: Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62: 960-968.","journal-title":"Arthritis Rheum"},{"key":"3243_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/ard.57.5.291","volume":"57","author":"PJ Barendregt","year":"1998","unstructured":"Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, Markusse HM: Fatigue in primary Sj\u00f6gren's syndrome. Ann Rheum Dis. 1998, 57: 291-295. 10.1136\/ard.57.5.291.","journal-title":"Ann Rheum Dis"},{"key":"3243_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.bbi.2009.06.151","volume":"23","author":"E Harboe","year":"2009","unstructured":"Harboe E, Tjensvoll AB, Vefring HK, Goransson LG, Kvaloy JT, Omdal R: Fatigue in primary Sj\u00f6gren's syndrome--a link to sickness behaviour in animals?. Brain Behav Immun. 2009, 23: 1104-1108. 10.1016\/j.bbi.2009.06.151.","journal-title":"Brain Behav Immun"},{"key":"3243_CR14","first-page":"1495","volume":"32","author":"E Theander","year":"2005","unstructured":"Theander E, Andersson SI, Manthorpe R, Jacobsson LT: Proposed core set of outcome measures in patients with primary Sj\u00f6gren's syndrome: 5 year follow up. J Rheumatol. 2005, 32: 1495-1502.","journal-title":"J Rheumatol"},{"key":"3243_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/03009740902973821","volume":"38","author":"R Baturone","year":"2009","unstructured":"Baturone R, Soto MJ, Marquez M, Macias I, de Oca MM, Medina F, Chozas N, Garc\u00eda-P\u00e9rez S, Gir\u00f3n-Gonz\u00e1lez JA: Health-related quality of life in patients with primary Sj\u00f6gren's syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol. 2009, 38: 386-389. 10.1080\/03009740902973821.","journal-title":"Scand J Rheumatol"},{"key":"3243_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/ard.2008.091256","volume":"68","author":"HF d'Elia","year":"2009","unstructured":"d'Elia HF, Bjurman C, Rehnberg E, Kvist G, Konttinen YT: Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sj\u00f6gren syndrome: an explanatory interventional study. Ann Rheum Dis. 2009, 68: 285-286. 10.1136\/ard.2008.091256.","journal-title":"Ann Rheum Dis"},{"key":"3243_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sj\u00f6gren's Syndrome: Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002, 61: 554-558. 10.1136\/ard.61.6.554.","journal-title":"Ann Rheum Dis"},{"key":"3243_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/rheumatology\/kep149","volume":"48","author":"TR Reksten","year":"2009","unstructured":"Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA: Cytokine and autoantibody profiling related to histopathological features in primary Sj\u00f6gren's syndrome. Rheumatology (Oxford). 2009, 48: 1102-1106. 10.1093\/rheumatology\/kep149.","journal-title":"Rheumatology (Oxford)"},{"key":"3243_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989, 46: 1121-1123.","journal-title":"Arch Neurol"},{"key":"3243_CR20","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J: Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005, 32: 811-819.","journal-title":"J Rheumatol"},{"key":"3243_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097\/00005650-199206000-00002.","journal-title":"Med Care"},{"key":"3243_CR22","volume-title":"PS: Power and sample size calculation","author":"WD Dupont","year":"2009","unstructured":"Dupont WD, Plummer WD: PS: Power and sample size calculation. 2009, Version 3.0, [http:\/\/biostat.mc.vanderbilt.edu\/wiki\/Main\/PowerSampleSize]"},{"key":"3243_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11136-010-9740-3","volume":"20","author":"H Peyre","year":"2010","unstructured":"Peyre H, Lepl\u00e8ge A, Coste J: Missing data methods for dealing with missing items in quality of life questionnaires. A comparison by simulation of personal mean score, full information maximum likelihood, multiple imputation, and hot deck techniques applied to the SF-36 in the French 2003 decennial health survey. Qual Life Res. 2010, 20: 287-300.","journal-title":"Qual Life Res"},{"key":"3243_CR24","first-page":"635","volume":"35","author":"EC Goligher","year":"2008","unstructured":"Goligher EC, Pouchot J, Brant R, Kherani RB, Avi\u00f1a-Zubieta JA, Lacaille D, Lehman AJ, Ensworth S, Kopec J, Esdaile JM, Liang MH: Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol. 2008, 35: 635-642.","journal-title":"J Rheumatol"},{"key":"3243_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.rdc.2008.08.010","volume":"34","author":"SJ Bowman","year":"2008","unstructured":"Bowman SJ: Patient-reported outcomes including fatigue in primary Sj\u00f6gren's syndrome. Rheum Dis Clin North Am. 2008, 34: 949-962. 10.1016\/j.rdc.2008.08.010. ix","journal-title":"Rheum Dis Clin North Am"},{"key":"3243_CR26","first-page":"283","volume":"8","author":"K Bjerrum","year":"1990","unstructured":"Bjerrum K, Prause JU: Primary Sj\u00f6gren's syndrome: a subjective description of the disease. Clin Exp Rheumatol. 1990, 8: 283-288.","journal-title":"Clin Exp Rheumatol"},{"key":"3243_CR27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/ard.2007.074203","volume":"67","author":"K Haldorsen","year":"2008","unstructured":"Haldorsen K, Moen K, Jacobsen H, Jonsson R, Brun JG: Exocrine function in primary Sj\u00f6gren syndrome: natural course and prognostic factors. Ann Rheum Dis. 2008, 67: 949-954.","journal-title":"Ann Rheum Dis"},{"key":"3243_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/art.21990","volume":"55","author":"J Champey","year":"2006","unstructured":"Champey J, Corruble E, Gottenberg JE, Buhl C, Meyer T, Caudmont C, Berg\u00e9 E, Pellet J, Hardy P, Mariette X: Quality of life and psychological status in patients with primary Sj\u00f6gren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum. 2006, 55: 451-457. 10.1002\/art.21990.","journal-title":"Arthritis Rheum"},{"key":"3243_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/rheumatology\/41.3.301","volume":"41","author":"JG Brun","year":"2002","unstructured":"Brun JG, Madland TM, Gjesdal CB, Bertelsen LT: Sj\u00f6gren's syndrome in an out-patient clinic: classification of patients according to the preliminary European criteria and the proposed modified European criteria. Rheumatology (Oxford). 2002, 41: 301-304. 10.1093\/rheumatology\/41.3.301.","journal-title":"Rheumatology (Oxford)"},{"key":"3243_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/ard.61.3.284","volume":"61","author":"HI Bax","year":"2002","unstructured":"Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW: Fatigue and immune activity in Sj\u00f6gren's syndrome. Ann Rheum Dis. 2002, 61: 284. 10.1136\/ard.61.3.284.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3487\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:22:49Z","timestamp":1728368569000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,10]]}},"alternative-id":["3243"],"URL":"https:\/\/doi.org\/10.1186\/ar3487","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]},"assertion":[{"value":"25 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R167"}}